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Abbreviations 
CDI – Clostridium difficile infection 
RC – radical cystectomy  
UTI – urinary tract infection  
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Abstract 
 
Introduction:  This study seeks to evaluate the incidence and associated risk factors for 
Clostridium difficile infection (CDI) in patients undergoing radical cystectomy (RC) for bladder 
cancer.  
Methods: We retrospectively reviewed a single institution bladder cancer database including all 
patients who underwent RC between 2010 and 2013.  CDI was diagnosed by detection of 
Clostridium difficile toxin B gene using polymerase chain reaction based stool assay in patients 
with clinically significant diarrhea within 90 days of the index operation.  A multivariable 
logistic regression model was used to identify demographics and perioperative factors associated 
with developing CDI.  
Results: Of the 552 patients who underwent RC, postoperative CDI occurred in 49 patients 
(8.8%) with a median time to diagnosis after RC of 7 days (IQR: 5-19).  Of the 122 readmissions 
for postoperative complications, 10% (n=12) were related to CDI.  Two patients died from sepsis 
directly related to severe CDI.  On multivariate logistic regression, the use of chronic antacid 
therapy (OR: 1.9, 95% CI 1.02 – 3.68, p=0.04) and antibiotic exposure greater than 7 days (OR: 
2.2, 95% CI: 1.11 – 4.44, p=0.02) were independently associated with developing CDI.  The use 
of preoperative antibiotics for positive urine culture within 30 days prior to surgery was not 
statistically significantly associated with development of CDI (p = 0.06).   
Conclusions: The development of CDI occurs in 8.8% of patients undergoing RC.  Our study 
demonstrates that use of chronic antacid therapy and long duration of antimicrobial exposure are 
associated with development of CDI.  Efforts focusing on minimizing antibiotic exposure in RC 
patients are needed and perioperative antimicrobial prophylaxis guidelines should be followed.     
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Introduction  
In the United States, Clostridium difficile, a spore-forming, gram-positive anaerobic 
bacillus, is the leading cause of nosocomial infectious diarrhea.1  Despite efforts on infection 
control and prudent antibiotic stewardship, the incidence of Clostridium difficile infection (CDI) 
continues to escalate in both the nosocomial and community settings.2, 3 Since the emergence of 
the hypervirulent NAP1/027 strain in recent years, there has been an increase in the severity of 
CDI, with more patients failing medical therapy and requiring emergent colectomy.2, 4, 5 
Recent epidemiologic data suggests that CDI is a growing burden among surgical patients 
and is associated with increased morbidity, mortality, hospital stay and health care costs.6, 7  The 
risk of CDI is highest among patients requiring intestinal tract manipulation or reconstruction, a 
population very similar to patients undergoing radical cystectomy (RC).6  Other major risk 
factors for CDI include advanced age and recent antibiotic exposure.4, 8-10  Bladder cancer 
patients tend to be older and require frequent antimicrobial prophylaxis for pre- and 
perioperative urinary tract instrumentation, therefore placing them at a higher risk for 
development of CDI.  
Recent studies utilizing data from community practice settings identified a CDI rate of 
1.3 – 1.7% in patients undergoing RC.10, 11 However, with RC becoming more regionalized to 
tertiary referral centers,12 the complications and incidence associated with CDI after RC at 
referral centers are rarely reported.  The purpose of this study is two-fold: to determine the 
incidence of CDI in a contemporary cohort undergoing RC at a high-volume tertiary referral 
center, and to identify the perioperative risk factors for development CDI in RC patients.         
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Materials and Methods 
 Following institutional review board approval, we conducted a retrospective review of 
patients undergoing RC between January 2010 and December 2013 at our institution for bladder 
cancer.  Patients undergoing cystectomy for non-oncological indications or with a history of 
chronic antibiotic use were excluded.  Patients with a preoperative urine culture demonstrating 
bacterial growth were treated with oral antibiotics within 30 days prior to RC.  Mechanical bowel 
preparations were only done in patients undergoing continent catheterizable urinary reservoir 
diversion (Indiana pouch). Oral antibiotic prophylaxis sterilizing gut flora was not used.   
All patients received a single-dose of cefoxitin within one hour of surgical incision.  For 
patients with a penicillin allergy or positive preoperative urine culture resistant to 
cephalosporins, other antibiotic regimens with coverage for gram negatives and anaerobes were 
administered (typically a fluoroquinolone in combination with metronidazole).  Perioperative 
antibiotic prophylaxis was extended beyond 24 hours postoperatively in select patients 
depending on surgeon preference.  All patients that qualified received pre and postoperative 
alvimopan, a peripheral opioid antagonist.  Postoperatively, patients were maintained on no oral 
intake on postoperative day 0 through 1 and given either proton-pump inhibitors or histamine-2 
antagonists.  Nasogastric tubes were removed on postoperative day 1 with allowance of limited 
clear liquids on postoperative day 2.  An unlimited clear liquid diet was given on postoperative 
day 3 until flatus, at which point patients were transitioned to a regular diet.   
The primary end point of this study was the development of CDI within 90 days of RC.  
CDI was diagnosed by detection of the Clostridium difficile toxin B gene using polymerase chain 
reaction based stool assay in patients with clinically significant diarrhea, which is defined as 
greater than three loose bowel movements in one day, or presence of pseudomembranous colitis 
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during exploratory laparotomy.  Hospital-wide CDI occurrences during the studied period were 
obtained from our Department of Infectious Diseases. Examined clinical and perioperative 
variables included age, gender, body mass index, preoperative/neoadjuvant chemotherapy, 
medical comorbidities, prior gastrointestinal surgery, preoperative urinary tract infection (UTI) 
and antibiotic use (within 30 days prior to RC), Charlson comorbidity index, chronic antacid 
therapy (including proton-pump inhibitors and histamine antagonists), urinary diversion type, 
operative time, estimated blood loss, perioperative blood transfusion, and perioperative antibiotic 
duration (defined as days of antibiotics received starting in the preoperative setting and ending at 
hospital discharge).   
Postoperative outcome variables included length of stay, readmission rate, need for 
postoperative antibiotics, septicemia/bacteremia, pyelonephritis/UTI, urinoma, hospital-acquired 
pneumonia, acute renal failure, prolonged ileus, wound infection/complication, intra-abdominal 
abscesses and death within 30 days of RC. 
Univariate analysis between CDI and clinical variables was assessed using Student’s t-
test for continuous variables and Pearson’s chi-square test for categorical variables.  To 
determine independent risk factors for CDI, we performed forward and backward stepwise 
logistic regressions using p ≤0.2 as the significance level required for inclusion. Variables 
identified as significant in the stepwise model were used in the final multivariate logistic 
regression model to examine the increased risk of CDI development.  Statistical analysis was 
performed using Stata® version 13.1 (StataCorp, College Station, Texas) with p<0.05 considered 
statistically significant.  
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Results 
 Of the 552 patients who underwent RC at our institution, 49 (8.8%) patients developed 
CDI.  The rate of CDI in RC patients increased from 6.4 per 1000 patients in 2010 to 16.5 per 
1000 patients in 2013 (Figure 1) and a small increase in hospital-wide CDI rate was also 
observed in the same time period (Table 1).  Of the 115 patients with clinically significant 
diarrhea, 42.6% tested positive for CDI.  The number of patients presenting with clinically 
significant diarrhea also increased between 2010 and 2013 (Table 1).  Median time to CDI 
diagnosis from RC was 7 days (IQR: 5-19).  Twelve patients (24.4%) developed CDI after 
discharge from their index hospitalizations.   
 Table 2 describes the clinical characteristics of the cohort.  Patients with CDI were more 
likely to use chronic antacid therapy and have a longer duration of perioperative antibiotic use 
but were less likely to undergo orthotopic neobladder diversion.  The rate of preoperative 
antibiotic use was higher in patients with CDI than those without CDI, but this difference was 
not statistically significant (p=0.06).   
The most common initial presenting symptom of CDI was diarrhea in 48 patients 
(97.9%).  Thirty-three patients (67.3%) were treated with either intravenous or oral 
metronidazole, and the remaining patients were treated with a combination of metronidazole and 
oral vancomycin.  Two patients with severe CDI and a history of fecal diversion were treated 
with vancomycin lavage via their end colostomies. 
In the stepwise logistic regression model, preoperative hemoglobin, chronic antacid 
therapy, perioperative antibiotic duration and urinary diversion type were considered significant 
(p<0.2), and therefore were included in the final multivariable logistic regression model.  
Patients on chronic antacid therapy had a 1.9 times increased odds of CDI when adjusting for 
preoperative hemoglobin, urinary diversion type, and duration of perioperative antibiotics 
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received (p=0.04, Table 3).  Additionally, patients who received more than 7 days of antibiotics 
(starting in the preoperative setting) had a 2.2 times increased odds of CDI when compared to 
patients who received no more than one day of antibiotics (p=0.02).  Since only patients with an 
Indiana pouch received mechanical bowel preparation, urinary diversion type was not 
significantly associated with CDI. This suggests that mechanical bowel preparation is unlikely an 
inciting factor for CDI.      
 Patients with CDI were more likely to have a longer hospital stay and higher readmission 
rate (Table 4).  Of the 122 readmissions, 10% (n=12) were readmitted for CDI.  The rate of 
postoperative antibiotic use during hospitalization was higher in patients with CDI than those 
without CDI but this did not reach statistical significance (p=0.08).  Patients with CDI had 
substantially more postoperative complications including urinoma, acute renal failure, wound 
infections and intra-abdominal abscesses.  Two deaths (4%) occurred as a result of CDI. One 
patient developed severe sepsis and end-organ failure from both CDI and other competing 
infections leading to withdrawal of care.  The second patient died of severe pseudomembranous 
colitis 3 days after RC.        
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Discussion 
This study provides contemporary data on the incidence and risk factors associated with 
CDI in patients undergoing RC.  At high-volume centers, the incidence of CDI in patients 
undergoing RC is largely unknown. In a recent review of 5,425 patients undergoing RC from 
more than 2,900 community hospitals, Calvert et al. identified a CDI incidence of 1.7%, which is 
higher than patients undergoing radical prostatectomy (0.02%) or nephrectomy (0.23%) but 
comparable to those undergoing colorectal procedures (1.5%).10, 13 A retrospective review of 180 
patients undergoing RC at a high-volume institution reported a higher CDI rate of 7.2% within 
30 days of surgery.14  Our study found that 8.8% of patients undergoing RC for bladder cancer 
developed CDI within 90 days of surgery.  Additionally, we demonstrated that nearly 10% of 
patient readmissions for postoperative complications were related to CDI, emphasizing the 
significant morbidity associated with this disease.                  
 Antimicrobial exposure is the most commonly cited risk factor for CDI development in 
surgical patients and the risk of CDI increases with longer duration of exposure.4, 9, 15, 16 A recent 
study from the Netherlands showed that the risk of CDI development is the highest during 
therapy and in the first month following antibiotic use.17  In congruence with these published 
findings, our study showed that the risk of CDI is highest after having received more than 7 days 
of perioperative antibiotics (HR: 2.2, p=0.02) compared to those who received only one day or 
less of antibiotics.  Our findings highlight the importance of minimizing antimicrobial exposure 
in RC patients and should serve as an important reminder to follow appropriate prophylaxis 
guidelines.     
 Antibiotic stewardship programs have been shown to decrease overall CDI rates,18, 19 but 
could a similar strategy be adopted in patients undergoing RC? For patients undergoing urinary 
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diversions, the American Urological Association recommends the use of antimicrobial 
prophylaxis for no more than 24 hours after surgery.20  Our study showed that only 49% of 
patients followed the appropriate guidelines on antimicrobial prophylaxis.  While the compliance 
rate at our institution seems low, the study by Calvert et al. also showed a comparable 
compliance rate of 44% in RC patients.10  Reasons for deviation from antimicrobial prophylaxis 
guidelines in RC patients include increased patient comorbidities, preoperative bacteriuria, 
difficult operations associated with fecal contamination, and indwelling hardware such as 
ureteral stents, catheters and/or surgical drains.21  Limiting antibiotic use in the postoperative 
setting seems logical but is difficult to apply universally as the incidence of postoperative 
infectious complications after RC patients remains high, and is reported in 16% to 38% of 
patients.22, 23   
 Limiting the use of preoperative antimicrobials in RC patients should be a priority.  
Approximately 30% of patients in our series received antibiotics for bacteriuria identified on 
preoperative urine cultures.  Though the 2005 guideline from Infectious Diseases Society of 
America recommends routine treatment of asymptomatic bacteriuria in patients undergoing 
urological procedures24, recent data from patients undergoing stone surgery have questioned the 
value of preoperative urine culture, as asymptomatic bacteriuria is a poor predictor of 
postoperative infection.25  Furthermore, several studies have shown that treatment of 
asymptomatic bacteriuria in bladder cancer patients undergoing outpatient urological procedures 
(ie. cystoscopy and intravesical therapy) is unnecessary as these patients did not have an 
increased risk of UTI.26, 27  A prospective trial on the utility of preoperative urine culture in 
patients undergoing RC is needed to fully address this issue. 
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Diarrhea in the immediate postoperative period is a common phenomenon after urinary 
diversion, however for patients undergoing a continent urinary reservoir procedure, this is often a 
result of anatomic loss of the ileocecal valve along the alimentary tract.  Since the most common 
trigger to test for CDI is diarrhea, we have found that less than half of our patients complaining 
of diarrhea had CDI.  Despite appropriate hand hygiene and implementation of CDI preventive 
measures at our institution, our study still demonstrated an increased incidence of CDI.  With the 
incidence of community-acquired CDI on the rise in recent years3, it is possible that some 
patients in our series are asymptomatic carriers of nontoxigenic Clostridium difficile.  Whether 
treatment is necessary for an asymptomatic carrier of Clostridium difficile remains 
controversial.28  One study has suggested that screening asymptomatic carriers at admission may 
lower in-hospital transmission rates of CDI.29  Thus, a prospective study for screening of 
asymptomatic carriers of Clostridium difficile at the time of radical cystectomy is warranted.                   
 The use of gastric acid reducers, such as histamine-2 antagonists or proton-pump 
inhibitors, has been suggested as a potential risk factor for the development of CDI.28, 30  A 
potential mechanism is that a vegetative form of Clostridium difficile spores is sensitive to 
gastric acid and an elevated gastric pH facilitates passage of spores to the colon.30  Our study 
also found that chronic antacid therapy was an independent risk factors for CDI within 90 days 
of RC (HR: 1.9, p=0.04).  This result should be interpreted with caution as one potential 
confounder is that all patients were treated with perioperative antacids - especially in patients 
with prolonged nasogastric decompression.  Nevertheless, in light of these findings, our 
institution has shifted away from giving patients perioperative antacids routinely since the 
completion of this study.                            
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The development of CDI in the postsurgical setting is associated with significant hospital 
morbidity and resource utilization.6, 16 In a study assessing the outcomes of hospital acquired 
adverse events in radical cystectomy patients, Kim et al. found that patients with CDI had a 
longer hospital stay by 9 days, and an increase in total hospitalization cost by $21,000 compared 
to those without adverse events.11  Similarly, our study found that CDI was associated with 
longer hospital stays, increased hospital-acquired infections, additional surgical and 
pharmacotherapies, and higher readmission rates.  Based on these findings, it is fair to assume 
that CDI leads to longer stay or higher overall postoperative complication rates, but the 
development of CDI may also be a consequence of these factors.  Therefore, it is difficult to 
identify a causality between CDI and postoperative complications with adequate certainty. 
    Several limitations of this study are noteworthy for discussion.  This study was 
conducted at a high-volume tertiary referral center for bladder cancer so the findings may not be 
applicable to other settings.  The increased incidence of CDI found in the present study may be a 
result of increased vigilance during the studied period or a reflection of increasing hospital-wide 
CDI occurrence.  These findings highlight the need to identify the incidence of CDI in the 
preoperative setting.  Additionally, RC in this study were performed by multiple experienced 
surgeons with different practice patterns and views regarding the use of perioperative antibiotics.  
Such factors may have contributed to the high incidence of CDI, but we did not study the 
individual rates of CDI related to each surgeon.  One major strength of the study is the detailed 
information available for each patient (ie. timing of preoperative, perioperative and postoperative 
antibiotics), which cannot be achieved by extracting data from large prospective databases.  We 
recognize that outcomes related to CDI cannot be randomized, but a prospective trial involving 
multiple referral centers for bladder cancer may overcome the limitations of the current study.    
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Conclusion 
We found that the rate of CDI in patients undergoing RC and urinary diversion for 
bladder cancer is higher than previously reported.  Additionally, the current study demonstrated 
that chronic antacid therapy and long duration of antibiotic exposure in the perioperative setting 
are independent predictors of CDI development in RC patients.  Efforts focusing on minimizing 
antibiotic exposure in RC patients are needed and perioperative antimicrobial prophylaxis 
guidelines should be followed.  These data also support future endeavors focusing on improving 
patient safety and reducing CDI in RC patients.      
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Figure 1. Incidence of CDI in RC patients by year of surgery 
 
Table 1.  RC patient and hospital-wide CDI rate by year  
Year No. of RC patients  
No. of stool toxin test 
sent (%)  
No. of CDI in RC 
patients (%) 
Hospital-wide CDI 
rate 
2010 150 21 (14) 9 (6) 1.0% 
2011 136 28 (21) 7 (5) 1.0% 
2012 130 26 (20) 12 (9) 1.2% 
2013 136 40 (26) 21 (15) 1.4% 
 
Table 2.   Patient and procedure characteristics  
Variable 
No CDI 
N=503 
CDI 
N=49 P-value 
Median age at surgery (IQR) 68 (58 – 76) 67 (60 – 75) 0.96 
No. Male gender (%) 399 (79.3) 35 (71.4) 0.20 
Median BMI, kg/m2 (IQR) 27.6 (24.2 – 31.5) 28.4 (24 – 34) 0.27 
No. urothelial bladder histology (%) 489 (97.2) 46 (93.8) 0.19 
No. preoperative chemotherapy (%) 127 (25.2) 10 (20.4) 0.60 
Median preoperative creatinine, mg/dL (IQR) 1.11 (0.9 – 1.32) 1.05 (0.85 – 1.3) 0.40 
No. preoperative hemoglobin, g/dL (IQR) 12 (10.5 – 13.3) 12.6 (10.9 – 13.7) 0.27 
No. prior gastrointestinal surgery (%) 75 (15.0) 9 (18.4) 0.53 
No. chronic antacid therapy (%) 106 (21.1) 18 (36.7) 0.01 
No. preoperative UTI (%) 137 (27.2) 17 (34.7) 0.32 
No. preoperative antibiotics 129 (25.7) 19 (38.8) 0.06 
Comorbidities    
No. stage III/IV chronic kidney disease (%) 47 (9.3) 7 (14.3) 0.31 
No. chronic obstructive pulmonary disease 
(%) 
56 (11.1) 8 (16.3) 0.35 
No. hypertension (%)  313 (62.2) 32 (65.3) 0.67 
No. diabetes (%) 130 (25.8) 13 (26.5) 0.92 
No. coronary artery disease (%) 86 (17.1) 12 (24.5) 0.20 
No. Charlson comorbidity index > 3(%) 79 (15.7) 12 (24.4) 0.11 
Median hours operative time (IQR) 4.8 (3.5 – 6.2) 4.6 (3.5 – 6.3) 0.86 
Median ml estimated blood loss (IQR) 500 (300 – 700) 500 (300 – 800) 0.24 
Diversion Type   0.04 
No. ileal conduit (%) 286 (56.9) 32 (65.3)  
No. Indiana pouch (%) 103 (20.5) 13 (26.5)  
No. orthotopic neobladder (%) 114 (22.7) 4 (8.2)  
Perioperative blood transfusion   0.28 
No. none (%) 287 (57.1) 22 (44.9)  
No. intraoperative only (%) 98 (19.5) 13 (26.5)  
No. postoperative only (%) 72 (14.3) 7 (14.3)  
No. intraoperative and postoperative (%) 46 (9.2) 7 (14.3)  
Days of antibiotics received*   0.005 
No. 1 day or less (%) 250 (49.7) 19 (38.8)  
No. 2 to 7 days (%) 179 (35.6) 14 (28.6)  
No. greater than 7 days (%) 74 (14.7) 16 (32.6)  
 
Table 3. Multivariable logistic regression of clinical characteristics associated with CDI 
 
Variable Hazard Ratio 95% CI p Value 
Diversion Type    
Ileal conduit Reference   
Indiana pouch 1.2 0.63 – 2.56 0.5 
Orthotopic neobladder 0.3 0.11 – 1.01 0.05 
Preoperative hemoglobin 1.1 0.98 – 1.33 0.09 
Preoperative antacid use 1.9 1.02 – 3.68 0.04 
Days of antibiotics received    
1 day or less Reference   
2 to 7 days 0.8 0.34 – 1.81 0.6 
Greater than 7 days 2.2 1.11 – 4.44 0.02 
Table 4. Postoperative outcomes of patients with and without CDI 
Variable 
No CDI 
N=503 
CDI 
N=49 p Value 
Median days length of stay (IQR) 7 (6 – 10) 9 (7 – 15) <0.001 
No. readmission (%) 102 (20.3) 20 (40.8) 0.002 
No. postoperative antibiotics (%) 154 (30.6) 21 (42.9) 0.08 
Complications    
No. septicemia/bacteremia (%) 46 (9.2) 10 (20.4) 0.02 
No. pyelonephritis/UTI (%) 43 (8.6) 14 (28.6) <0.001 
No. urinoma (%) 4 (0.8) 6 (12.2) <0.001 
No. hospital acquired 
pneumonia (%) 
27 (5.4) 2 (4.1) 0.52 
No. acute renal failure (%) 27 (5.4) 11 (22.5) <0.001 
No. prolonged ileus (%) 90 (17.9) 11 (22.5) 0.43 
No. wound infection (%) 61 (12.1) 11 (22.5) 0.04 
No. intra-abdominal abscess (%) 25 (5.0) 8 (16.3) 0.001 
No. death within 30 days (%) 6 (1.2) 2 (4.1) 0.15 
 
 
 
 
 
